文献速递瓣膜外科先天性心脏病外科

外科Melody二尖瓣:婴儿不可修复二尖瓣疾病的范式转变

Surgical Melody Mitral Valve: A Paradigm Shift for Infants With Unrepairable Mitral Valve Disease.
PubMed 文献 · Ann Thorac Surg · 2024-05-27

本研究分析2014至2023年接受Melody瓣膜行二尖瓣置换(MelodyMVR)的25例小儿童患者,中位年龄6.3个月、中位体重6.36 kg。MelodyMVR提供合理的早中期生存率(6个月死亡率8.3%,1年12.5%,5年17.6%)和较高的成功桥接至机械二尖瓣置换率,起搏器、出血和血栓需求少,但早期Melody功能衰退需早期再次二尖瓣置换。

要点

  • 25例小儿童接受MelodyMVR,中位年龄6.3个月,中位体重6.36 kg。
  • 6个月、1年、5年死亡率分别为8.3%、12.5%、17.6%。
  • 约50%患者在MelodyMVR后3.5年内接受机械二尖瓣置换。

核心结论

  • MelodyMVR为小儿童提供合理的早中期生存率和较高的成功桥接至机械二尖瓣置换率。
  • MelodyMVR与极少的起搏器需求、出血和血栓相关。
  • 早期Melody功能衰退需早期再次二尖瓣置换,但可以极低并发症和死亡率完成。

研究设计与样本

  • 回顾性分析2014年至2023年接受MelodyMVR的患者,共25例。
  • 采用Kaplan-Meier分析无移植生存率,Fine and Gray亚分布法量化累积发生率。

主要发现

  • 中位年龄6.3个月(四分位距4.4-15.2个月),中位体重6.36 kg(四分位距4.41-7.57 kg)。
  • 15例(60%)为先天性二尖瓣疾病,13例(52%)以二尖瓣反流为主。
  • 植入Melody中位直径16 mm(四分位距14-18 mm)。
  • 6个月、1年、5年死亡率分别为8.3%(95%CI 2.2%-29.4%)、12.5%(95%CI 4.2%-33.9%)、17.6%(95%CI 7.0%-40.7%)。
  • 2例(8%)住院存活者需早期Melody更换;竞争风险分析显示约50%患者在MelodyMVR后3.5年内接受机械二尖瓣置换。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Melody valve (Medtronic, Minneapolis, MN) for mitral valve replacement (MVR) (MelodyMVR) has been an effective strategy to treat unrepairable mitral valve disease in small children. This study analyzed survival, durability, and complications of the MelodyMVR strategy. METHODS: Patients who underwent MelodyMVR between 2014 and 2023 were included. Transplant-free survival was analyzed with Kaplan-Meier analysis. The Fine and Gray subdistribution method was applied to quantify the cumulative incidence. RESULTS: Twenty-five patients underwent MelodyMVR. Median age and weight were 6.3 months (interquartile range, 4.4-15.2 months) and 6.36 kg (interquartile range, 4.41-7.57 kg). Fifteen patients (60%) had congenital mitral valve disease and 13 (52%) had dominant mitral regurgitation. The median diameter of the implanted Melody was 16 mm (interquartile range, 14-18 mm). Mortality at 6 months, 1 year, and 5 years was 8.3% (95% CI, 2.2%-29.4%), 12.5% (95% CI, 4.2%-33.9%), and 17.6% (95% CI, 7.0%-40.7%), respectively. Two hospital survivors (8%) required early Melody replacement. Competing risk analysis showed that ∼50% of patients underwent mechanical MVR by 3.5 years after MelodyMVR. Freedom from bleeding and thrombosis at 4 years was 87.5% (95% CI, 74.2%-100%). Eleven patients underwent subsequent mechanical MVR with no deaths. One (9%) required pacemaker implantation after mechanical MVR. CONCLUSIONS: MelodyMVR provides reasonable early and medium-term survival in small children and a high rate of successful bridge to mechanical MVR. MelodyMVR is associated with minimal pacemaker requirement, bleeding, and thrombosis. Early Melody functional deterioration necessitates early repeat MVR, which can be achieved with minimal morbidity and mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Honjo O, Chetan D, Fan CS, et al. Surgical Melody Mitral Valve: A Paradigm Shift for Infants With Unrepairable Mitral Valve Disease. Ann Thorac Surg. 2024. PMID: 38810907. doi:10.1016/j.athoracsur.2024.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。